论文部分内容阅读
目的探讨吡格列酮对2型糖尿病患者血清髓过氧化物酶(Myeloperoxidase,MPO)及胰岛素抵抗等指标的影响。方法30名2型糖尿病患者加用吡格列酮15mg/d治疗12周,测定治疗前后的空腹血糖、空腹胰岛素、糖化血红蛋白、血脂、血清髓过氧化物酶,计算胰岛素抵抗指数。结果吡格列酮干预后的空腹血糖、血清髓过氧化物酶、胰岛素抵抗指数均显著下降(P<0.05),糖化血红蛋白有下降趋势(P=0.07),血脂各项指标均无显著变化。结论吡格列酮能显著降低2型糖尿病患者的血清髓过氧化物酶水平及胰岛素抵抗程度,提示其可用于预防2型糖尿病患者的动脉粥样硬化。
Objective To investigate the effects of pioglitazone on serum myeloperoxidase (MPO) and insulin resistance in type 2 diabetic patients. Methods 30 patients with type 2 diabetes mellitus were treated with pioglitazone 15 mg / d for 12 weeks. Fasting blood glucose, fasting insulin, glycosylated hemoglobin, lipids, and serum myeloperoxidase were measured before and after treatment. Insulin resistance index was calculated. Results The fasting blood glucose, serum myeloperoxidase and insulin resistance index of pioglitazone group were significantly decreased (P <0.05), while the levels of HbA1c were decreased (P = 0.07). There was no significant change in each index of blood lipid. Conclusion Pioglitazone can significantly reduce the level of serum myeloperoxidase and insulin resistance in type 2 diabetic patients, suggesting that it may be used to prevent atherosclerosis in type 2 diabetic patients.